Related Experiment Video
Updated: Jun 13, 2025

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
Published on: August 16, 2024
Dissection of triple-negative breast cancer microenvironment and identification of potential therapeutic drugs using
Weilun Cheng1, Wanqi Mi2, Shiyuan Wang3
1Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Abstract:
Breast cancer remains a leading cause of mortality in women worldwide. Triple-negative breast cancer (TNBC) is a particularly aggressive subtype characterized by rapid progression, poor prognosis, and lack of clear therapeutic targets. In the clinic, delineation of tumor heterogeneity and development of effective drugs continue to pose considerable challenges. Within the scope of our study, high heterogeneity inherent to breast cancer was uncovered based on the landscape constructed from both tumor and healthy breast tissue samples. Notably, TNBC exhibited significant specificity regarding cell proliferation, differentiation, and disease progression. Significant associations between tumor grade, prognosis, and TNBC oncogenes were established via pseudotime trajectory analysis. Consequently, we further performed comprehensive characterization of the TNBC microenvironment. A crucial epithelial subcluster, E8, was identified as highly malignant and strongly associated with tumor cell proliferation in TNBC. Additionally, epithelial-mesenchymal transition (EMT)-associated fibroblast and M2 macrophage subclusters exerted an influence on E8 through cellular interactions, contributing to tumor growth. Characteristic genes in these three cluster cells could therefore serve as potential therapeutic targets for TNBC. The collective findings provided valuable insights that assisted in the screening of a series of therapeutic drugs, such as pelitinib. We further confirmed the anti-cancer effect of pelitinib in an orthotopic 4T1 tumor-bearing mouse model. Overall, our study sheds light on the unique characteristics of TNBC at single-cell resolution and the crucial cell types associated with tumor cell proliferation that may serve as potent tools in the development of effective anti-cancer drugs.
Insights
Triple-negative breast cancer (TNBC) shows high heterogeneity and specific cell proliferation patterns. Targeting malignant epithelial cells and their microenvironment, like with pelitinib, offers new therapeutic strategies for aggressive breast cancer.
Area of Science:
- Oncology
- Genomics
- Cancer Biology
Background:
- Breast cancer is a leading cause of female mortality worldwide.
- Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and limited therapeutic options.
- Tumor heterogeneity and microenvironment complexity present significant challenges in TNBC treatment.
Purpose of the Study:
- To investigate the heterogeneity and cellular landscape of breast cancer, focusing on TNBC.
- To identify specific cell types and molecular pathways driving TNBC progression.
- To explore potential therapeutic targets and drugs for TNBC treatment.
Main Methods:
- Single-cell RNA sequencing of tumor and healthy breast tissue.
- Pseudotime trajectory analysis to associate oncogenes with tumor grade and prognosis.
- Comprehensive characterization of the TNBC microenvironment.
- In vivo validation using an orthotopic 4T1 tumor-bearing mouse model.
Main Results:
- High heterogeneity was observed in breast cancer, with TNBC showing specific proliferation and differentiation patterns.
- A highly malignant epithelial subcluster (E8) was identified, strongly associated with TNBC cell proliferation.
- Epithelial-mesenchymal transition (EMT)-associated fibroblasts and M2 macrophages influence E8, promoting tumor growth.
- Pelitinib demonstrated anti-cancer effects in a TNBC mouse model.
Conclusions:
- TNBC exhibits unique single-cell characteristics and crucial cell types driving proliferation.
- Specific genes within malignant epithelial cells, fibroblasts, and macrophages are potential therapeutic targets.
- Pelitinib shows promise as an effective therapeutic drug for TNBC.

